Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
https://t.co/EVbxkdDTgJ
Go, Gameto, go, go, go! A new chapter in women's health.
Bloomberg: "The company has the potential to drive the biggest transformation in women’s health since the birth control pill."
"Gameto aims to improve the egg-freezing experience. The technique, which uses stem cells that have been engineered into ovarian support cells, is intended to free patients from the grueling two weeks of injections that prompt ovaries to make enough eggs during fertility treatment. In a Phase 3 trial, patients are only given one or two injections, after which their eggs are extracted and matured by the engineered cells."
"The treatment is already available to patients in Mexico, Peru and Australia, and has been cleared by regulators in nine more countries [and] may also be helpful in treating symptoms of menopause and maintaining ovarian health." — https://t.co/xR0ypESpLQ
Today's news: "Ferring Pharmaceuticals has signed a $1.4 billion deal to buy Gameto Inc. Ferring is a Swiss maker of drugs used for in-vitro fertilization and reproductive medicine. It’s betting that with its global access to fertility clinics and pharmaceutical distribution, it will be able to popularize Gameto’s therapy"
"Interest in women’s health, historically under studied and underfunded, has heated up among pharmaceutical companies, driven in part by the commercial success of GLP-1 weight loss drugs among women." — https://t.co/S4Jfspe1ip
Congratulations Dr. Dina Turner and the Gameto team!